Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
Phase Ib Clinical Trial on the Safety of Immunotherapy With Autologous Dendritic Cells Primed With Lysate Allogeneic Tumor Lines in Patients With Diffuse Intrinsic Pontine Glioma (DIPG)
Sponsor: Fundació Sant Joan de Déu
Listed as NCT02840123, this PHASE1 trial focuses on Diffuse Intrinsic Pontine Glioma and remains ongoing. Sponsored by Fundació Sant Joan de Déu, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Mar 2020 — Jan 2021 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundació Sant Joan de Déu
- Institut d'Investigacions Biomèdiques August Pi i Sunyer
For direct contact, visit the study record on ClinicalTrials.gov .